The Federal Government of Nigeria has intensified preparations for the introduction and nationwide rollout of Lenacapavir (LEN) as a Pre-Exposure Prophylaxis (PrEP) option, in a renewed effort to strengthen HIV prevention and accelerate progress towards epidemic control in the country.
Lenacapavir, a long-acting injectable HIV prevention medication administered only twice a year, is expected to expand prevention options and improve adherence among individuals at substantial risk of HIV infection.
According to an official status update, Nigeria has established coordinated implementation strategies aimed at ensuring a structured, safe, and quality-assured rollout of the innovative PrEP option across priority states.
In a statement signed by Mrs Toyin Aderibigbe, the government noted that country remains on course for a phased introduction of Lenacapavir PrEP, supported by regulatory approval, strengthened health system preparedness, trained healthcare personnel, and sustained community engagement initiatives.
“Several key milestones have already been achieved to support the planned rollout.
“These include the completion of landscape and readiness assessments in ten states namely Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, the Federal Capital Territory (FCT), Gombe, Kano, Kwara and Lagos States.
“In addition, regulatory approval has been secured from the National Agency for Food and Drug Administration and Control (NAFDAC), clearing the way for implementation within Nigeria’s healthcare system.
“The government also conducted a National Training of Trainers programme in Abuja, followed by step-down training for healthcare workers across states selected for implementation to ensure effective service delivery.
“To enhance public awareness and promote acceptance, Information, Education and Communication (IEC) materials have equally been developed to support community sensitisation and demand creation”.
Authorities further disclosed that Lenacapavir commodities are expected to arrive in Nigeria by March 2026, marking a critical step towards operational deployment.
The introduction of Lenacapavir is expected to significantly strengthen Nigeria’s HIV prevention response by providing a convenient long-acting alternative to daily oral PrEP, particularly for populations facing adherence challenges.